

## Invitation to presentation of Oasmia's year-end report 2021 on February 24

Oasmia Pharmaceutical will publish its year-end report for 2021 on February 24, 2022, at 08.00 am CET. The company will hold a conference call and an online presentation on the same day at 10.00 am CET. The call will be hosted by CEO Francois Martelet and CFO Fredrik Järsten. The presentation will be in English and followed by a question-and-answer session.

The conference call will be broadcast live on the web via the link:  
<https://tv.streamfabriken.com/oasmia-pharmaceutical-q4-2021>

Telephone number for the conference call is:  
SE: +46850558354  
UK: +443333009035  
US: +16467224903

### For more information:

Oasmia Pharmaceutical AB  
Francois Martelet, Chief Executive Officer  
Phone: +46 18-50 54 40  
E-mail: [IR@oasmia.com](mailto:IR@oasmia.com)

Consilium Strategic Communications  
Jonathan Birt, Chris Welsh, Ashley Tapp  
Phone: +44 (0)20 3709 5700  
E-mail: [oasmia@consilium-comms.com](mailto:oasmia@consilium-comms.com)

### About Oasmia Pharmaceutical AB

Oasmia is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Oasmia has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Oasmia's shares are traded on Nasdaq Stockholm (OASM). To find out more about Oasmia please visit [www.oasmia.com](http://www.oasmia.com).

### Attachments

---

[Invitation to presentation of Oasmia's year-end report 2021 on February 24](#)

---